30 October 2019
Melbourne, Australia: VivaZome Therapeutics Pty Ltd (“VivaZome”) is pleased to announce that Dr David Haylock has been appointed as Chief Executive Officer (CEO), effective as of 01 November, 2019.
Dr Haylock has collaborated with VivaZome since 2017 and joined the Company as Chief Scientific Officer (CSO) in July, 2019. In his role as CEO, Dr Haylock will maintain his CSO function.
Previously Dr Haylock has held senior leadership and management roles in organisations such as CSIRO, the Australian Stem Cell Centre, the Peter MacCallum Cancer Centre and the Institute for Medical and Veterinary Sciences. He has a wealth of experience in stem cell biology, cellular therapies and cell manufacturing, all of which are directly relevant to VivaZome’s exosome therapies.
“I am delighted to be given the opportunity to lead the VivaZome team as it explores this new field of therapeutics and develops cutting-edge technology”, stated Dr Haylock.
Executive Director, Craig Newton, said “I am excited to see David step up to the CEO role and have every confidence that he will take the Company to the next level over the coming years.”
Mr Newton will move to a non-Executive Director position with the Company as of 01 November.
For further information, contact:
VivaZome Therapeutics Pty Ltd
Dr Ian Nisbet, Chairman
ian.nisbet@vivazome.com
Phone: +61 (0) 431 709 121
